DiagnaMed Announces Resignation of Director and Grant of Stock Options
08. Januar 2025 17:00 ET
|
DiagnaMed Holdings Corp.
TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF) announces that Elyssia Patterson has resigned from the board. The...
DiagnaMed and QIMC to Advance Hydrogen Production Technology at the Ville Marie Clean Natural Renewable Hydrogen Project
08. Januar 2025 08:00 ET
|
DiagnaMed Holdings Corp.
TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading innovator in hydrogen production technologies and artificial...
DiagnaMed Partners with Texas Tech University to Pioneer Hydrogen Innovation
07. Januar 2025 08:00 ET
|
DiagnaMed Holdings Corp.
TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading innovator in hydrogen-producing technologies and artificial...
DiagnaMed and EIREX Collaborate to Develop and Commercialize Novel Modular Technology Producing Hydrogen from Water
14. November 2024 08:00 ET
|
DiagnaMed Holdings Corp.
TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on molecular hydrogen and AI...
DiagnaMed Announces Stock Option Grants and Shares for Debt Settlement
13. November 2024 17:45 ET
|
DiagnaMed Holdings Corp.
TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on molecular hydrogen and AI...
DiagnaMed Files U.S. Patent Application for Novel Methods of Producing Molecular Hydrogen
07. November 2024 08:00 ET
|
DiagnaMed Holdings Corp.
Advancing molecular hydrogen for neurological and mental health disorders Expects its molecular hydrogen product to be ready for use in December 2024 TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) --...
DiagnaMed Advancing the Medical Potential of Hydrogen
30. Oktober 2024 08:00 ET
|
DiagnaMed Holdings Corp.
TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on brain health, announces its...
DiagnaMed Expands with Drug and Clinical Research AI Platform
21. August 2024 08:00 ET
|
DiagnaMed Holdings Corp.
Leveraging proprietary EEG data from previous and future research studies with BRAIN AGE® Brain Health AI Accelerating clinical trial development and discovering potential novel treatments for...
DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
15. August 2024 08:00 ET
|
DiagnaMed Holdings Corp.
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is...
DiagnaMed Cancels Previously Announced Private Placement
03. Juli 2024 16:00 ET
|
DiagnaMed Holdings Corp.
TORONTO, July 03, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI,...